STUDY OF THE MUTAGENIC PROPERTIES OF THE DRUG DIOMAST-KRS WITH REPEATED EXPOSURE

Abstract

This article considers the drug Diomast-KRS consisting of two components: component 1 - recombinant bovine interferons, component 2 - dioxidine, and vitamin A is also included in both components, from the point of view of its potential mutagenic activity with repeated use. The assessment was carried out using a micronucleus test, the experiment was performed on white non-linear laboratory mice (n=30). Five (5) experimental groups were formed, 6 individuals in each group. The study showed that in the studied doses (conditionally therapeutic and 1/10 of LD50) with repeated administration, there were no statistically significant changes in the quantitative content of micronuclei and the percentage of polychromatophilic erythrocytes in the bone marrow of experimental animals relative to control indicators. It was also shown that the use of individual components of the drug did not lead to a change in cytogenetic stability, which indicated the absence of a mutagenic effect in the drug Diomast-KRS under the studied dosing regimen.